



Annual DALYs by Region, 1997 - 2006 (Percent Growth over the prior year)




East and Southern Africa continue to propel PSI's strong growth, with annualized growth rates of 25% and 32%, respectively, over the last 10 years.

Change in PSI' s Health Impact, 1997 - 2006




Although HIV represents the largest proportion of PSI's portfolio, it has been PSI's slowest growing health sector.

2006 DALYs by Product




Together, condoms and nets account for more than three-quarters of PSI's health impact.


Profile of HIV/AIDS Health Impact



Large populations and high prevalence rates contribute to the concentration of 50% of HIV DALY gains in 4 countries.




Over the last five years, HIV DALY gains have contracted or stabilized in most regions and it has become our slowest growing health area. Only Southern Africa (+22% annually) and the Americas (+31%) continued to grow substantially between 2002 and 2006.




Condoms continue to generate the lion's share of our HIV DALY gains. Despite rapid growth last year, VCT (+35%), Lubricant (+63%) and Nevirapine (+113%) constitute only a small proportion of PSI's HIV DALYs.

Profile of Family Planning Health Impact


Geographic Concentration of 2006 Family Planning Health Impact
DALYs Gained: 2.6 Million DALYs



1997-2006 Annual Family Planning DALYs by Region




1997-2006 Annual Family Planning DALYs by Product




Product diversification and moderate geographic distribution suggest the FP portfolio is positioned for sustained, if modest, growth in health impact.


Profile of Malaria Health Impact



PSI's Malaria health impact is highly concentrated with more than one-third of malaria DALYs gained in Kenya alone and 70% of DALYs gained in just 4 countries.




While East Africa is clearly driving the growth of Malaria health impact, all regions continue to grow rapidly with Southern Africa and Nigeria both doubling DALY gains from 2005 to 2006.




Innovation, through the introduction of new products, has been key to our gains in Malaria, including the KO123 retreatment kits launched in 2006.


Profile of Water Borne Disease Health Impact



Only one year after launching SWS and PuR, Ethiopia already plays a prominent role in the health impact of PSI's water programs.







The decline in WCA's water health impact is due to, and parallels, the decline of ORS' health impact. Other regions have grown with the launch of SWS products.




SWS is learning to fly on its own: its DALY gains in 2006 came through programs largely funded by donors and built on earlier investments by PSI. Declines in ORS health impact are due largely to flagging donor interest and procurement problems.

Sales Growth for Products Launched in or before 2001




Detail on Fastest Growing Products - Sales Growth by Product, 2001 - 2006





(year 2001 = 100)



Sales Growth by Product (launched after 2003)
(year 2004 = 100)



Sales by Country (Top 5), 1997 - 2006



2006 Condom Sales per Capita by Country

